“From Vulnerable Plaque to Vulnerable Patient” Summit
Towards Establishing
The Screening for Heart Attack Prevention and Education (SHAPE) Guideline

A satellite event during the annual scientific sessions of the American Heart Association,
Saturday, November 12th, 2005, Hyatt Regency Hotel – Dealey Auditorium, Dallas, TX

Agenda

6:30-7:45 am  On-Site Registration and Breakfast

Welcome

8:00–8:15 am  From Vulnerable Plaque to Vulnerable Patient: Our Mission is Eradication of Heart Attack
Morteza Naghavi, M.D.  Chairman of the SHAPE Task Force and President of the Association for
Eradication of Heart Attack, Houston, TX
An overview of the detection and treatment of the vulnerable patient: what we have learned in
the past 5 years and what to expect in the next 5 years.

Opening Remarks

8:15-8:30 am  Prediman K. Shah, M.D.  Professor of Medicine at UCLA and Chief of Cardiology, Cedars-Sinai
Medical Center, Los Angeles, CA
Screening for Subclinical Atherosclerosis: a New Opportunity in Primary Prevention

8:30-8:50 am  Valentin Fuster, M.D., Ph.D.  President of the World Heart Federation and Professor of
Medicine, Mount Sinai Medical Center, New York, NY
Identification of the High-Risk Plaque Versus Burden of Disease in the Vulnerable Patient

Session I  Beyond Risk Factors: Screening for Atherosclerosis

Chair:  Prediman K. Shah, M.D.  Professor of Medicine at UCLA and Chief of Cardiology, Cedars-Sinai Medical
Center, Los Angeles, CA

Co-Chair:  Harvey Hecht, M.D.  Professor of Clinical Medicine, Albert Einstein College of Medicine, and Director of Cardiovascular CT Lab, Lenox Hill Heart &
Vascular Institute, New York, NY

8:50-9:20 am  On behalf of the Editorial Committee of the SHAPE Task Force
Erling Falk, M.D., Ph.D.  Professor of Cardiovascular Pathology, Aarhus University, Denmark

Risk Assessment based on Subclinical Disease rather than Risk Factors - The SHAPE Paradigm. A comprehensive risk
assessment must include subclinical disorders of the arterial wall, blood, and myocardium; sufficient evidence is currently available only for the arterial wall
(atherosclerosis).
Latest Evidence on Coronary Calcium and Carotid IMT Imaging

9:20-9:35 am  Predictive Value of Coronary Calcium Scoring
Matthew Budoff, M.D.  Vice President, Society of Atherosclerosis Imaging, and Associate Professor of Medicine and Director of Preventive Cardiology, Harbor-UCLA Medical Center, Los Angeles, CA

9:35-9:50 am  Predictive Value of Carotid IMT Measurement
Tasneem Naqvi, M.D.  Associate Professor of Medicine, Associate Director, Cardiac Noninvasive Lab, Cedars-Sinai Medical Center, UCLA School of Medicine, LA, CA

9:50-10:05 am  The Role of CCS and CIMT in Monitoring Progression and Regression of Atherosclerosis
Allen Taylor, M.D.  Associate Professor of Medicine and Director of Atherosclerosis Imaging Center, Walter Reed Army Medical Center, Washington D.C.

10:05-10:15 am  Q&A and Conclusion by the Chairmen

10:15-10:30 am  Coffee Break

Session II  Cost Effectiveness of Screening for Atherosclerosis

Chair:  George Diamond, M.D.  Professor of Medicine, UCLA, Los Angeles, CA
Co-Chair:  Daniel Mark, M.D., M.P.H.  Professor of Medicine and Director of the Outcomes Research, Duke University Medical Center, Durham, NC

10:30-10:45 am  Principles of Cost Effectiveness for Screening Tests
Mark Hlatky, M.D.  – Professor of Health Research and Policy and of Medicine, Department of Health Research and Policy Stanford University, Stanford, CA

10:45-11:00 am  Preventive Screening for Subclinical Disease –Comparing Atherosclerosis with Neoplasia
Daniel Lane, M.D., Ph.D.  Member, Lipid/Lipoprotein Laboratory, OMRF, Oklahoma City, and Hematology-Oncology Specialist, San Antonio, TX

11:00-11:15 am  Cost Effectiveness of CRP Screening
Paul Ridker, M.D.  Professor of Medicine and Preventive Cardiology, Harvard University and Brigham Women Hospital, Boston, MA

11:15-11:30 am  On Behalf of the SHAPE Task Force Cost Effectiveness Committee
Cost Effectiveness of SHAPE; Screening for Atherosclerosis is More Cost Effective than Screening for Risk Factors of Atherosclerosis
Leslee Shaw, Ph.D.  Director of Outcome Research at Cedars-Sinai Medical Center, Division of Cardiology and Department of Imaging, Los Angeles, CA

11:30-12:00 am  Q&A and Commentary Slides by the Chairmen

12:00 -12:30 pm  Lunch
Session III  
Emerging Developments and Future Directions in the Detection of Vulnerable Patients and Vulnerable Plaques

Chair: Gregg Stone, M.D. Professor of Medicine at Columbia University Medical Center and Co-Director of Cardiovascular Research Foundation, New York, NY

Co-Chair: Thomas Brady, M.D. Professor of Medicine and Radiology, Director of Radiology Research, Massachusetts General Hospital, Harvard University, Boston, MA

12:30-12:45 pm  Designer Genes: From Plaque to Attack – Introducing novel genomic and proteomic markers of atherosclerosis versus atherothrombosis.  
Pascal Goldschmidt, M.D. Professor and Chairman, Department of Medicine, Duke University Durham, NC

12:45-1:00 pm  Search for Systemic Biomarkers of Endothelial Dysfunction - Microalbuminuria, impaired reactive hyperemia, circulating micro-particles, circulating progenitor cells…?  
Arshed Quyyumi, M.D. Professor of Medicine and Vascular Biology, Division of Cardiology, Emory University, Atlanta, GA

1:00-1:15 pm  Noninvasive CT Imaging and Angiography – The next big thing in diagnostic cardiology has arrived!!!  
Harvey Hecht, M.D. Professor of Clinical Medicine, Albert Einstein College of Medicine, and Director of Cardiovascular CT, Lenox Hill Heart & Vascular Institute, New York, NY

1:15-1:30 pm  Emerging CT Technologies Are Racing to Meet the Future of Noninvasive Cardiology – Multi-Detector (64, 128, 256…), Multi-Energy, Ultra-Fast CTs, and Smart Contrast Agents; What to expect in year 2006 and after.  
Stephen Achenbach, M.D. Assistant Professor of Medicine, Department of Internal Medicine II (Cardiology), University of Erlangen-Nurnberg, Erlangen, Germany

1:30-1:45 pm  Noninvasive Molecular Imaging of Atherosclerotic Plaques with MRI – The future lies in molecular imaging, the question is which molecule!  
Zahi Fayad, Ph.D. Associate Professor of Radiology and Director of Cardiovascular Imaging Research, Mount Sinai Medical Center, New York, NY

1:45-2:00 pm  Noninvasive Molecular Imaging of Atherosclerotic Plaques with PET-CT – No single imaging technology will solve our problem; the answer lies in combined modalities.  
Ahmed Tawakol, M.D. Associate Director, Nuclear Cardiology, Massachusetts General Hospital; Co-director, CIMIT Innovative Technologies in Cardiovascular Disease Program, Boston, MA

2:00-2:15 pm  Noninvasive Molecular Imaging of Atherosclerotic Plaque with SPECT-CT – The Future is Clear!  
Daniel Berman, M.D. Professor of Medicine at UCLA and Chief of Nuclear Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA

2:15-2:30 pm  Emerging Intravascular Imaging Technologies (Thermography, OCT, NIR Spectroscopy, iMRI,…) for the Detection of Vulnerable Plaques – What have we learned in the past 5 years?  
Robert Schwartz, M.D. Medical Director, Minnesota Cardiovascular Research Institute, Minneapolis Heart Inst Foundation, Minneapolis, MN
2:30-2:45 pm  IVUS; The Ultimate Existing Intravascular Imaging Technology for Plaque Characterization – Luminology, Virtual Histology, Palpography, Shear Stress Mapping, and Vasa Vasorum Imaging All in One!
   **Patrick Serruys, M.D.**  Professor of Medicine and Director of Catheterization Laboratory, Thorax Center, Erasmus University, Rotterdam, the Netherlands

2:45-3:00 pm  The Ultimate IVUS: Imaging Plaque Morphology and Inflammation; Contrast Enhanced IVUS Enables Combined Assessment of Plaque Structure and Activity/Inflammation.
   **Stephane Carlier, M.D., Ph.D.**  Assistant Professor of Medicine and Director, Intravascular Imaging & Physiology, Columbia University and Cardiovascular Research Foundation, New York

3:00-3:15 pm  Detection of the Vulnerable Blood – Circulating tissue factor, micro-particles, and others.
   **Juan Badimon, Ph.D.**  Professor of Medicine, and Director of Cardiovascular Biology Research Lab., Mount Sinai School of Medicine, New York, NY

3:15-3:30 pm  Q&A and Commentary Slides by the Chairmen

3:30–3:45 pm  Coffee Break

**Session IV**  Emerging Developments and Future Directions in the Treatment of Vulnerable Patients and Vulnerable Plaques

Chair:  **Jay Cohn, M.D.**  Professor of Medicine and Director of Rasmussen Center for Cardiovascular Disease Prevention, University of Minnesota, Minneapolis, MN

Co-Chair:  **Martin Leon, M.D.**  Professor of Medicine at Columbia University Medical Center, and Director of Cardiovascular Research Foundation, New York, NY

3:45-4:00 pm  Emerging Atherosclerosis Drugs to Watch, and Challenges and Promises of “PolyPill”
   **Wolfgang Koenig, M.D., Ph.D.**  Professor of Medicine and Preventive Cardiology, University of Ulm, Ulm, Germany

4:00–4:15 pm  HDL Raising Therapies: The Next Big Wave in the Treatment of Atherosclerosis I
   **Mohammad Navab, Ph.D.**  Professor, Atherosclerosis Research Program, Division of Cardiology, University of California Los Angeles, CA

4:15–4:30 pm  The Next Big Wave in the Treatment of Atherosclerosis II
   **Prediman K. Shah, M.D.**  Professor of Medicine at UCLA and Chief of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA

4:30-4:45 pm  Focal Therapy with Drug Eluting Stents: A Preemptive Treatment Choice for Vulnerable Plaques
   **Pedro Moreno, M.D.**  Associate Professor of Medicine, Director of Interventional Cardiology Research, Mount Sinai Medical Center, New York, NY
Drug Eluting Stents: An Ounce of Prevention for a Pound of Flesh!
Sanjay Kaul, M.D.  Professor of Medicine and Director, Vascular Physiology and Thrombosis Research Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA

Segmental Therapy with Non-ionizing Radiations and Photo-Dynamic Compounds
Ron Waksman, M.D.  Professor of Medicine and Director of Cardiovascular Research Institute, Washington Hospital, Washington D.C.

Pan Coronary Therapy with Intrapericardial Drug Delivery
Sergio Waxman, M.D. – Associate Professor of Medicine, Tuft University, New England Medical Center, Boston, MA

Comments: Focus on both Vulnerable Plaque and Vulnerable Patient; Invasive screening for non-culprit but vulnerable plaques after cardiac events complements noninvasive screening in the asymptomatic population. By James Muller, M.D. – A Pioneering Vulnerable Plaque Investigator, and Founder, CEO and Chief Medical Officer of InfraReDx.

Eradication of heart attack is an attainable goal not a fantasy. Join AEHA and lead the way to make heart attack history.

Social Hour -- Drinks and Cocktails --
All faculty members of the VP Summit are invited to the dinner reception of the 2nd Atherosclerosis Vaccine Symposium held by AEHA at the same hotel.

Guest Faculty: Raymond Bahr, M.D., Jasenka Demirovic, M.D., Ph.D., Stanislav Emelianov, Ph.D., Raimund Erbel, M.D., Charles Feldman, Ph.D., James Goldstein, M.D., Victoria Herrera, M.D., Bijoy Khandheria, M.D., Michael LaMonte, Ph.D., M.P.H., Robert Mendes, M.D., Narula Jagat, M.D., Axel Schmermund, M.D., Christodoulos Stefanadis, M.D., Peter Stone, M.D., Momtaz Wassef, Ph.D., and Chun Yuan, Ph.D.